Functional Impurity Assessment

Functional impurity assessment evaluates pharmacological activity of trace contaminants and degradation products potentially affecting therapeutic safety or efficacy. Pharmacological screening identifies impurities possessing off-target receptor activity, genotoxicity, or immunogenicity. Concentration-response studies quantitate impurity potency relative to active ingredient. Risk-based approaches prioritise highest-risk impurities for detailed characterisation.

Genotoxic impurity identification employs in vitro bacterial reverse mutation testing and mammalian cell assays detecting mutagenic degradation products. Thresholds of toxicological concern establish acceptable impurity limits protecting patient safety. Mechanistic investigation distinguishes pharmacologically inert contaminants from functionally active species. Regulatory submissions identify and characterise potentially functional impurities. Post-approval impurity monitoring via stress testing ensures emerging contaminants receive appropriate assessment. Preclinical and clinical safety conclusions account for total impurity burden including identified and unidentified species.